A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 30 Jul 2017 Results of PK/PD model pooled data from two phase II studies published in the Clinical Pharmacology and Therapeutics
    • 27 Jun 2012 Results published in the European Respiratory Journal.
    • 18 Apr 2012 Official title amended as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top